Versican Plus Pi/L4R

Country: European Union

Language: Icelandic

Source: EMA (European Medicines Agency)

Active ingredient:

canine parainfluenza virus, leptospira and rabies virus.

Available from:

Zoetis Belgium S.A.

ATC code:

QI07AJ

INN (International Name):

canine parainfluenza virus, leptospira and rabies virus

Therapeutic group:

Hundar

Therapeutic area:

Ónæmislyf fyrir canidae, Lifandi og óvirkt veiru og bakteríu bóluefni

Therapeutic indications:

Virk bólusetningar hundar frá sex vikur aldri til að koma í veg fyrir klínískum merki og draga úr veiru skilst að valda með því að hundur inflúensubróðir veira, til að koma í veg fyrir klínískum merki, sýkingum og þvagi valda með því að Leptospira serovars bratislava, canicola, grippotyphosa og icterohaemorrhagiae og að koma í veg fyrir dauða, klínískum merki og sýking valda með hundaæði veira.

Product summary:

Revision: 5

Authorization status:

Leyfilegt

Authorization date:

2014-07-30

Patient Information leaflet

                                17
B. FYLGISEÐILL
18
FYLGISEÐILL:
VERSICAN PLUS PI/L4R FROSTÞURRKAÐ STUNGULYF OG DREIFA, DREIFA, FYRIR
HUNDA
1.
HEITI OG HEIMILISFANG MARKAÐSLEYFISHAFA OG ÞESS FRAMLEIÐANDA
SEM BER ÁBYRGÐ Á LOKASAMÞYKKT, EF ANNAR
Markaðsleyfishafi:
Zoetis Belgium SA
Rue Laid Burniat 1
1348 Louvain-la-Neuve
BELGÍA
Framleiðandi sem ber ábyrgð á lokasamþykkt:
Bioveta, a.s.,
Komenského 212,
683 23 Ivanovice na Hané,
TÉKKLAND
2.
HEITI DÝRALYFS
Versican Plus Pi/L4R frostþurrkað stungulyf og dreifa, dreifa, fyrir
hunda
3.
VIRK(T) INNIHALDSEFNI OG ÖNNUR INNIHALDSEFNI
Hver 1 ml skammtur inniheldur:
VIRK INNIHALDSEFNI:
FROSTÞURRKAÐ LYF (LIFANDI VEIKLAÐ):_ _
_ _
_ _
_ _
_ _
LÁGMARK
HÁMARK_ _
Hundaparainflúensuveira tegund 2, stofn CPiV-2-Bio 15
10
3,1
TCID
50
*
10
5,1
TCID
50
DREIFA (ÓVIRKJUÐ):
_Leptospira interrogans_
sermihópur Icterohaemorrhagiae
sermigerð Icterohaemorrhagiae stofn MSLB 1089
ALR** títri ≥1:51
_Leptospira interrogans _
sermihópur Canicola
sermigerð Canicola, stofn MSLB 1090
ALR** títri ≥1:51
_Leptospira kirschneri _
sermihópur Grippotyphosa
sermigerð Grippotyphosa
_,_
stofn MSLB 1091
ALR** títri ≥1:40
_Leptospira interrogans_
sermihópur Australis
_ _
sermigerð Bratislava
_,_
stofn MSLB 1088
ALR** títri ≥1:51
Hundaæðiveira, stofn SAD Vnukovo-32
≥2,0 a.e.***
ÓNÆMISGLÆÐAR:
Álhýdroxíð
1,8–2,2 mg.
*
Skammtur sem dugar til að sýkja 50% smitaðra vefjarækta (tissue
culture infectious dose 50%).
**
Mótefnaörkekkjunarpróf (antibody micro agglutination-lytic
reaction).
*** Alþjóðlegar einingar.
Frostþurrkað lyf: svampkennt hvítt efni.
Dreifa: bleiklitaður með fíngerðu botnfalli.
19
4.
ÁBENDING(AR)
Virk ónæmingaraðgerð hjá hundum frá 8-9 vikna aldri:
-
til að koma í veg fyrir klínísk einkenni (útferð úr nefi og
augum) af völdum
hundaparainflúensuveiru og draga úr útskilnaði veirunnar,
-
til að koma í veg fyrir klínísk einkenni og sýkingu af völdum
_L.interrogans_
sermihóps Australis
sermigerð Bratislava og koma í veg fyrir 
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
VIÐAUKI I
SAMANTEKT Á EIGINLEIKUM LYFS
2
1.
HEITI DÝRALYFS
Versican Plus Pi/L4R frostþurrkað stungulyf og dreifa, dreifa, fyrir
hunda
2.
INNIHALDSLÝSING
Hver 1 ml skammtur inniheldur:
VIRK INNIHALDSEFNI:
FROSTÞURRKAÐ LYF (LIFANDI VEIKLAÐ):_ _
LÁGMARK
HÁMARK_ _
Hundaparainflúensuveira tegund 2, stofn CPiV-2-Bio 15
10
3,1
TCID
50
*
10
5,1
TCID
50
DREIFA (ÓVIRKJUÐ):
_Leptospira interrogans_
sermihópur Icterohaemorrhagiae
sermigerð Icterohaemorrhagiae stofn MSLB 1089
ALR** títri ≥1:51
_Leptospira interrogans _
sermihópur Canicola
sermigerð Canicola, stofn MSLB 1090
ALR** títri ≥1:51
_Leptospira kirschneri _
sermihópur Grippotyphosa
sermigerð Grippotyphosa
_,_
stofn MSLB 1091
ALR** títri ≥1:40
_Leptospira interrogans_
sermihópur Australis
_ _
sermigerð Bratislava
_,_
stofn MSLB 1088
ALR** títri ≥1:51
Hundaæðiveira, stofn SAD Vnukovo-32
≥2,0 a.e.***
*
Skammtur sem dugar til að sýkja 50% smitaðra vefjarækta (tissue
culture infectious dose 50%).
**
Mótefnaörkekkjunarpróf (antibody micro agglutination-lytic
reaction).
*** Alþjóðlegar einingar.
ÓNÆMISGLÆÐAR:
Álhýdroxíð
1,8–2,2 mg.
Sjá lista yfir öll hjálparefni í kafla 6.1.
3.
LYFJAFORM
Frostþurrkað stungulyf og dreifa, dreifa.
Útlit lyfsins er sem hér segir:
Frostþurrkað lyf: svampkennt hvítt efni.
Dreifa: hvítleit með fíngerðu botnfalli.
4.
KLÍNÍSKAR UPPLÝSINGAR
4.1
DÝRATEGUNDIR
Hundar
4.2
ÁBENDINGAR FYRIR TILGREINDAR DÝRATEGUNDIR
Virk ónæmingaraðgerð hjá hundum frá 8-9 vikna aldri:
-
til að koma í veg fyrir klínísk einkenni (útferð úr nefi og
augum) af völdum
hundaparainflúensuveiru og draga úr útskilnaði veirunnar,
3
-
til að koma í veg fyrir klínísk einkenni og sýkingu af völdum
_L.interrogans_
sermihóp Australis
sermigerð Bratislava og koma í veg fyrir útskilnað í þvagi,
-
til að koma í veg fyrir klínísk einkenni og draga úr sýkingu af
völdum
_L. interrogans_
sermihóps
Canicola sermigerð Canicola og
_L. interrogans_
sermihóps Icterohaemorrhagiae s
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 17-05-2019
Summary of Product characteristics Summary of Product characteristics Bulgarian 17-05-2019
Public Assessment Report Public Assessment Report Bulgarian 20-10-2014
Patient Information leaflet Patient Information leaflet Spanish 17-05-2019
Public Assessment Report Public Assessment Report Spanish 20-10-2014
Patient Information leaflet Patient Information leaflet Czech 17-05-2019
Public Assessment Report Public Assessment Report Czech 20-10-2014
Patient Information leaflet Patient Information leaflet Danish 17-05-2019
Public Assessment Report Public Assessment Report Danish 20-10-2014
Patient Information leaflet Patient Information leaflet German 17-05-2019
Public Assessment Report Public Assessment Report German 20-10-2014
Patient Information leaflet Patient Information leaflet Estonian 17-05-2019
Public Assessment Report Public Assessment Report Estonian 20-10-2014
Patient Information leaflet Patient Information leaflet Greek 17-05-2019
Public Assessment Report Public Assessment Report Greek 20-10-2014
Patient Information leaflet Patient Information leaflet English 17-05-2019
Public Assessment Report Public Assessment Report English 20-10-2014
Patient Information leaflet Patient Information leaflet French 17-05-2019
Public Assessment Report Public Assessment Report French 20-10-2014
Patient Information leaflet Patient Information leaflet Italian 17-05-2019
Public Assessment Report Public Assessment Report Italian 20-10-2014
Patient Information leaflet Patient Information leaflet Latvian 17-05-2019
Public Assessment Report Public Assessment Report Latvian 20-10-2014
Patient Information leaflet Patient Information leaflet Lithuanian 17-05-2019
Summary of Product characteristics Summary of Product characteristics Lithuanian 17-05-2019
Public Assessment Report Public Assessment Report Lithuanian 20-10-2014
Patient Information leaflet Patient Information leaflet Hungarian 17-05-2019
Summary of Product characteristics Summary of Product characteristics Hungarian 17-05-2019
Public Assessment Report Public Assessment Report Hungarian 20-10-2014
Patient Information leaflet Patient Information leaflet Maltese 17-05-2019
Public Assessment Report Public Assessment Report Maltese 20-10-2014
Patient Information leaflet Patient Information leaflet Dutch 17-05-2019
Public Assessment Report Public Assessment Report Dutch 20-10-2014
Patient Information leaflet Patient Information leaflet Polish 17-05-2019
Public Assessment Report Public Assessment Report Polish 20-10-2014
Patient Information leaflet Patient Information leaflet Portuguese 17-05-2019
Summary of Product characteristics Summary of Product characteristics Portuguese 17-05-2019
Public Assessment Report Public Assessment Report Portuguese 20-10-2014
Patient Information leaflet Patient Information leaflet Romanian 17-05-2019
Public Assessment Report Public Assessment Report Romanian 20-10-2014
Patient Information leaflet Patient Information leaflet Slovak 17-05-2019
Public Assessment Report Public Assessment Report Slovak 20-10-2014
Patient Information leaflet Patient Information leaflet Slovenian 17-05-2019
Summary of Product characteristics Summary of Product characteristics Slovenian 17-05-2019
Public Assessment Report Public Assessment Report Slovenian 20-10-2014
Patient Information leaflet Patient Information leaflet Finnish 17-05-2019
Public Assessment Report Public Assessment Report Finnish 20-10-2014
Patient Information leaflet Patient Information leaflet Swedish 17-05-2019
Public Assessment Report Public Assessment Report Swedish 20-10-2014
Patient Information leaflet Patient Information leaflet Norwegian 17-05-2019
Summary of Product characteristics Summary of Product characteristics Norwegian 17-05-2019
Patient Information leaflet Patient Information leaflet Croatian 17-05-2019
Public Assessment Report Public Assessment Report Croatian 20-10-2014